8-K

================================================================================
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934



                       DATE OF REPORT - November 30, 2001
                        (Date of Earliest Event Reported)

                           COLUMBIA LABORATORIES, INC.
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

                           Commission File No. 1-10352


             Delaware                                        59-2758596
- --------------------------------------------------------------------------------
     (State of Incorporation)                             (I.R.S. Employer
                                                         Identification No.)

220 South Orange Avenue, 2nd Floor
      Livingston, New Jersey                                    07039
- --------------------------------------------------------------------------------
      (Address of principal                                   Zip Code
        executive offices)


       Registrant's telephone number, including area code: (973) 994-3999




================================================================================

NY2:\1102870\01\NMZ@01!.DOC\37965.0012



Item 5.       Other Events.

On November 30, 2001, Columbia Laboratories, Inc. issued the press release
attached hereto as Exhibit 99.1.


Item 7.       Financial Statements, Pro Forma Financial Information and
              Exhibits.

                  (c)      Exhibits.

                           99.1     Press Release dated November 30, 2001.














                                       2


                                    SIGNATURE
                                    ---------

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.


Date:  December 4, 2001

                                         COLUMBIA LABORATORIES, INC.



                                         By: /s/ David L. Weinberg
                                             ------------------------------
                                             Name:  David L. Weinberg
                                             Title: Chief Financial Officer

















                                       3

EX-99.1

                                                                    Exhibit 99.1


Press Release

Columbia Laboratories Gives Notice of Breach of the Crinone License and Supply
Agreement to Ares Trading S.A.

Columbia Reconfirms Crinone Product Release

LIVINGSTON, N.J.--(BUSINESS WIRE)--Nov. 30, 2001--Columbia Laboratories
(AMEX:COB) today announced that it has served upon Ares Trading S.A. and Serono
S.A. a Notice of Breach of the Crinone License and Supply Agreement and put Ares
on notice that they must cure all breaches within 60 days, or the agreement will
be terminated. Columbia further announced the release of three additional
batches of Crinone 8% for marketing in all territories covered by the agreement,
which fulfills all open supply commitments to Ares Trading.

In this Notice, the company sets forth, among other things, the following
material breaches of the agreement against Ares Trading, Serono Inc. and Serono
S.A.: (1) failure to adequately market Crinone 4% and 8%, (2) failure to
properly inform and appropriately process customer complaints regarding Crinone
4% and 8%, (3) failure to re-launch recently released Crinone 8% and (4) the
purported rejection of the re-validated Crinone batches released to Ares on
October 19, 2001. If the above-mentioned breaches are not resolved within 60
days, Columbia plans to terminate the License and Supply Agreement and market
the product directly.

The company has successfully completed all testing and analysis required for
release of Crinone as defined within the NDA and other regulatory files. These
tests were conducted at the only approved facility for Crinone, PCI
Laboratories, a division of Cardinal Healthcare, and confirmed that the
viscosity issue leading to the recall of selected batches of Crinone in April of
this year has been corrected. On Tuesday, the company received additional data,
which re-confirmed that the product manufactured under the company's
re-validation protocol continues to meet all product specifications including
viscosity.

"Due to Serono's inappropriate rejection of and failure to market the
re-validated batches of Crinone that were released to Serono on October 19,
2001, we have no other alternative but to proceed with this course of action,"
commented Fred Wilkinson, president and chief executive officer of Columbia
Laboratories. "We intend to pursue all legal opportunities within the confines
of the agreement to demand that Serono fulfills its obligations."

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company
dedicated to research and development of women's health care and endocrinology
products, including those intended to treat infertility, dysmenorrhea,
endometriosis and hormonal deficiencies. Columbia is also developing hormonal
products for men and a buccal delivery system for peptides. Columbia's products
primarily utilize the company's patented bioadhesive delivery technology.

                                       4


This press release contains statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Those statements include statements regarding the intent, belief or current
expectations of the company and its management team. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those projected in the forward-looking statements. Such
risks and uncertainties include, among other things, the successful revalidation
of the Crinone manufacturing process, timely and successful completion of
clinical studies, competitive economic and regulatory factors in the
pharmaceutical and health care industry, the outcome of the Serono litigation,
general economic conditions and other risks and uncertainties that may be
detailed, from time-to-time, in Columbia's reports filed with the Securities and
Exchange Commission.


Contact:
Columbia Laboratories, Inc., Livingston
James Apostolakis, 212/588-1900
David Weinberg, 973/994-3999
or
In-Site Communications, Inc.
Lisa Carlton-Wilson, 212/759-3929









                                       5